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Background: Rectus sheath hematoma is an uncommon but potentially serious bleeding complication that can
occur spontaneously or as a result of anticoagulation administration.
Case presentation: Case number one: A 62 year old chronically ill Caucasian female develops a rectus sheath
hematoma seven days after hospital discharge. The previous hospitalization included low molecular weight heparin
administration for deep vein thrombosis prophylaxis. The patient ultimately chooses comfort care and expires due
to sepsis and respiratory failure. Case number two: A 79 year old Caucasian male develops a rectus sheath
hematoma during hospital admission where LMWH is used for deep vein thrombosis prophylaxis. He is managed
conservatively; however, his hematocrit drops from 46 to 25.8%. Case number three: A 44 year old chronically ill
Caucasian female is treated with therapeutic low molecular weight heparin for recent deep vein thrombosis during
a hospital admission. She develops a large rectus sheath hematoma requiring embolization as well as blood
transfusion.
Conclusion: We believe this reflects an underreported significant cause of morbidity and mortality with low
molecular weight heparin administration. We review the pathophysiology of rectus sheath hematoma as well as its
presentation, diagnosis, and treatment. We identify at-risk populations and proposed contributing factors. We also
discuss factors leading to underreporting as well as preventive strategies implemented at our institution.
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For greater than a decade, prophylactic administration of
low molecular weight heparin (LMWH) has risen for hos-
pitalized patients and is an encouraged practice of deep
vein thrombosis (DVT) prophylaxis. Therapeutic dosing is
considered the standard medical care for many common
diagnoses such as pulmonary embolism, acute DVT, acute
coronary syndrome, and atrial fibrillation [1]. Well estab-
lished adverse outcomes from LMWH include gastrointes-
tinal bleeding, intracranial hemorrhage, thrombocytopenia,
and retroperitoneal bleeding [2]. Rectus sheath hematoma
(RSH) is considered an uncommon bleeding complication
that can occur spontaneously, after trauma, or as a result
of anticoagulation therapy. Cases of RSH associated with
subcutaneous LMWH injection have been reported [3-7].
We present a case series of three patients with RSH associ-
ated with subcutaneous enoxaparin injection. These were* Correspondence: klitton@utmck.edu
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unless otherwise stated.confirmed by computed tomography (CT) at our facility
during a three month period. We propose that RSH may
be an underreported, significant cause of morbidity and
perhaps mortality in the setting of LMWH use. Diagnostic
and therapeutic interventions as well as preventive strat-
egies we have implemented at our institution are discussed.
Case presentation
Case number one
A 62 year old Caucasian female was hospitalized for six
days for treatment of a chronic obstructive pulmonary
disease (COPD) exacerbation. Management included ste-
roids and antibiotics. Home medications included clopi-
dogrel for coronary artery disease. Her weight was 46.58
kilograms with a BMI of 17.7 and an estimated glomeru-
lar filtration rate (eGFR) of 60.65 ml/min. During the
hospitalization she was treated for DVT prophylaxis
with enoxaparin 40 mg by subcutaneous injection daily.
Seven days after discharge, the patient returned to the
emergency department complaining of diffuse abdominall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Sullivan et al. BMC Research Notes 2014, 7:586 Page 2 of 4
http://www.biomedcentral.com/1756-0500/7/586pain, increasing abdominal girth, and anterior wall
bruising. An abdominal CT scan confirmed a large RSH
(Figure 1). Both general surgery and interventional radi-
ology were consulted. She was managed conservatively.
Her hematocrit dropped from 34.8 to 25.3%; however,
she declined transfusion of blood products. During the
course of her stay, the patient experienced acute hyp-
oxic respiratory failure and did not wish to be intubated.
Her medical status deteriorated and, with support from
her family, the patient chose to be made comfortable
with minimal supportive care. She expired due to sepsis
and respiratory failure two days after re-admission.Figure 2 Left rectus sheath hematoma. A CT scan of the abdomen
and pelvis revealing a large left rectus sheath hematoma (arrow).Case number two
A 79 year old male Caucasian was admitted for worsening
dyspnea and management of atrial fibrillation with rapid
ventricular rate and COPD exacerbation. His clinical
course was further complicated by resistant gram negative
and gram positive pneumonia and hypoxic respiratory fail-
ure. His weight was 59 kilograms with a BMI of 18 and
initially his eGFR was 41.98 ml/min. He received subcuta-
neous abdominal injections of both prophylactic enoxa-
parin 30 mg and insulin sliding scale therapy. On day 2,
his eGFR was calculated at 53.94 and his enoxaparin dose
was increased to 40 mg daily.
On day 5, he was noted to have abdominal pain and a
noncontrast CT scan confirmed a left RSH (Figure 2) that
expanded considerably over 12 hours on follow up CT.
Interventional radiology was consulted but ultimately the
patient was managed conservatively with fluid resuscitation
and close observation. His hematocrit dropped from 46 to
25.8%. The patient was discharged after 15 days to a long
term acute care facility for further management of his re-
spiratory failure and healthcare associated pneumonia.Figure 1 Left rectus sheath hematoma. A CT scan of the abdomen
and pelvis revealing a large left rectus sheath hematoma (arrow).Case number three
An obese 44 year old Caucasian female with multiple
chronic medical problems was readmitted to our facility
from a ventilator capable extended care facility for sepsis
and acute on chronic hypoxic respiratory failure. Co-
morbidities included spina bifida and central obesity
with a BMI of 27. She was admitted on warfarin therapy
for a history of recent deep vein thrombosis; however,
she was subtherapeutic, with an International Normal-
ized Ratio (INR) of 1.59. She was, therefore, treated with
full dose enoxaparin 80 mg by subcutaneous injection
twice daily. Her eGFR was 148.65 ml/min. Coumadin
was held as the patient was treated with anitfungal and
antimicrobial therapy that could prolong her INR.
On day 8, she complained of abdominal pain and a CT
scan confirmed a large right RSH (Figure 3). Repeat CT
scan one day later showed extension of the hematoma and
concern for possible active arterial extravasation. Both gen-
eral surgery and interventional radiology were consulted.
The patient underwent a failed attempt at embolization due
to access complications. Due to hemorrhagic shock she re-
quired transfusion with 10 units of RBCs and pressure sup-
port ventilation in the intensive care unit. Her hematocrit
dropped from 34.9 to 20.6%. Anticoagulation was reversed
with fresh frozen plasma, vitamin K, and one dose of re-
combinant factor VIIa. The patient subsequently under-
went successful embolization with thrombin and coiling of
the right inferior epigastric artery by vascular surgery two
days after the initial hematoma. Serial CT scans confirmed
no further bleeding. After two weeks, anticoagulation
therapy was reinstituted without further evidence of
bleeding. The patient was ultimately discharged to a
long term acute care facility for continued management
of her chronic respiratory failure.
Figure 3 Right rectus sheath hematoma with extension. A CT
scan of the abdomen and pelvis revealing a large right rectus
sheath hematoma (arrow 1) with extension into the lateral
abdominal wall (arrow 2).
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Rectus sheath hematoma occurs due to bleeding in the
rectus sheath. This bleeding occurs either from a tear of
the rectus muscle or from damage to its blood supply,
including the superior and inferior epigastric arteries
and branches. The rectus abdominis muscle and the epi-
gastric arteries are surrounded by an aponeurotic sheath
above the arcuate line. Below the arcuate line the poster-
ior sheath compromises only the transversalis fascia and
thus, bleeding from the inferior epigastric artery in this
area can be more severe. The superior and inferior epigas-
tric arteries anastomose around the umbilicus creating a
higher concentration of vessels in this area [8,9]. There is
some evidence to suggest that aging and deconditioning of
the abdominal muscles results in protuberant tissue with
increased vascularity which may predispose the elderly to
vessel injury and bleeding [4,5].
Causes of RSH can include trauma, surgery, vigorous
muscle contractions from coughing or straining, intraab-
dominal injections, and pregnancy. RSH can also occur
spontaneously. Risk factors include anticoagulation ther-
apy, cough, older age, thin body habitus, central obesity,
pregnancy, female gender, recent abdominal surgery, ex-
ternal trauma, medical conditions causing coagulopathy,
persons receiving multiple types of abdominal subcuta-
neous injections, and renal insufficiency [3-5,7,8].
The incidence of RSH is suspected to be on the rise;
however, this is difficult to determine. In 1999, Klingler
et al. found an incidence of 1.8% among 1257 hospital-
ized patients being evaluated by ultrasound for abdominal
pain [10]. Cherry et al.’s case review at the Mayo Clinic
found 126 patients over a 10 year period and illustrates
the difficulty in determining an actual incidence rate [3].Enoxaparin drug information provided by Lexi-Comp,
Inc. reports that major hemorrhage occurs less than 1 to
4% and includes intracranial, retroperitoneal or intraocular
hemorrhage. It also reports injection site hematoma as a
local adverse reaction occurring at a rate of 9%. It is un-
clear whether RSH is grouped into the major hemorrhage
or local injection site category. Lack of a ICD-9 code and
lumping the diagnosis into “major bleeding” categories in
large trials such as TIMI and GUSTO makes identifying
the true incidence difficult [5].
Symptoms of RSH include abdominal pain, nausea, and
vomiting. The symptoms can mimic conditions such as di-
verticulitis, appendicitis, cholecystitis, incarcerated in-
guinal hernia, ovarian cyst torsion, or acute pancreatitis.
Physical exam often reveals a painful, firm abdominal
mass corresponding to the rectus sheath. Ecchymosis does
not tend to appear until 2–5 days following the hematoma
[3,4,7,11]. When unrecognized, RSH has resulted in in-
appropriate invasive procedures such as open laparotomy;
however, criteria have been proposed to prevent this.
Maharaj et al. recommended using physical exam maneu-
vers to differentiate intraabdominal from abdominal wall
pathology. One such maneuver, described by Carnett in
1962, involves palpation of the tender abdomen in the su-
pine and half-sitting positions, respectively. With this
maneuver, intraabdominal processes will be most tender
supine and will be protected by the contracted rectus
muscle when the patient is sitting. Abdominal wall pro-
cesses will remain tender in both positions [12].
Two main imaging modalities for diagnosis of RSH are
ultrasound and CT. Ultrasound is not as sensitive as CT;
however, it is typically more rapid and does not expose the
patient to radiation. CT is useful because it is 100% sensi-
tive and specific and can determine the presence of active
bleeding [10,13]. In order to better classify radiologic find-
ings and suggest appropriate management strategies for
findings documented, Berna et al. has described a classifi-
cation system of RSH based on CT results. This classifica-
tion system is divided into three types of RSH. Type I
TSH represents an intramuscular, unilateral hematoma
not dissecting into a fascial plane. Type II RSH represents
an intramuscular, unilateral or bilateral hematoma which
does not dissect into the fascial plane, but without occupa-
tion of the prevesical space. Type III RSH may or may not
involve muscle, and blood can be seen within the transver-
salis fascia, peritoneum, and prevesical space [14].
Treatment of Type I and Type II RSH is usually con-
servative. Treatment of Type III RSH frequently involves
blood transfusion [14]. Invasive treatment includes angi-
ography with embolization or surgical management with
exploration, hematoma evacuation, and ligation of bleed-
ing vessels; however, this is only indicated if the RSH is
progressive or if the patient is hemodynamically unstable
despite adequate resuscitation [13]. Morbidity related to
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as well as prolonged hospital stay and increased health-
care costs. Mortality data is difficult to determine given
the lack of data tracking [3,7,15].
The association between RSH and LMWH is not well
understood. The SYNERGY trial has demonstrated an in-
creased bleeding risk when switching from one type of
heparin product to another (i.e. from unfractionated hep-
arin to LMWH), but this was not a contributing factor in
our cases [15]. Injection technique has been implicated in
numerous case reports [3-7]. The Lovenox® (Sanofi-aventis
U.S., Bridgewater, NJ) package insert advises that the injec-
tion sites should alternate between the left and right an-
terolateral and left and right postero-lateral abdominal
wall, avoiding the umbilicus by at least two inches. There
is a warning not to inject intramuscularly. Instructions
also state that the whole length of the needle should be in-
troduced into a skin fold and advise that the skin fold
should be held throughout the injection interval. Consid-
eration of alternate injection sites such as the posterior
deltoid has been suggested for higher risk patients [5,12].
The facts of these cases were reviewed for quality im-
provement and were presented at a morbidity and mor-
tality conference at our facility. This led to a systems
review and re-education of nursing staff, including injec-
tion technique, site selection, and identification of higher
risk patients. In addition, the eGFR is now calculated
and reported with basic lab work, allowing for ease of
renal dose adjustments.
Conclusion
A series of cases at our institution highlight RSH as a ser-
ious potential complication of subcutaneous LMWH ad-
ministration. Complicated coding schematics, with no
existing ICD-9 code for the purpose of documentation
and tracking of such events, may attribute to underreport-
ing of RSH in both the inpatient and outpatient setting.
Diagnosis of RSH can be accomplished with ultrasound or
CT and management of RSH is usually conservative.
We encourage other practitioners and institutions to
be aware of RSH and support the emphasis on staff and
caregiver training as an important factor in its preven-
tion. Recognition of higher risk patients, careful injection
site selection, and proper injection technique should be in-
cluded in this training.
Consent
For case number one, written, informed consent was ob-
tained from the patient’s next of kin for publication of
this case report and any accompanying images. A copy
of the written consent is available for review by the
Editor-In-Chief of this journal.
For case numbers two and three, written, informed
consent was obtained from the patients for publicationof these case reports and accompanying images. A copy
of the written consent is available for review by the
Editor-in-Chief of this journal.
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